To assess whether PIKfyve inhibition enhances efficacy of ACT, we established s.c. tumors derived from OVA-expressing B16-F10 cells and infused CD8+ T cells derived from OT1 mice into the tumor-bearing syngeneic hosts (Fig. 5A). Here, PIKFYVE is linked to neoplasm.